IL148089A0 - Baff receptor (bcma), an immunorgulatory agent - Google Patents

Baff receptor (bcma), an immunorgulatory agent

Info

Publication number
IL148089A0
IL148089A0 IL14808900A IL14808900A IL148089A0 IL 148089 A0 IL148089 A0 IL 148089A0 IL 14808900 A IL14808900 A IL 14808900A IL 14808900 A IL14808900 A IL 14808900A IL 148089 A0 IL148089 A0 IL 148089A0
Authority
IL
Israel
Prior art keywords
immunorgulatory
bcma
agent
baff receptor
baff
Prior art date
Application number
IL14808900A
Other languages
English (en)
Original Assignee
Biogen Inc
Apotech R & D Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27386828&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL148089(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Inc, Apotech R & D Sa filed Critical Biogen Inc
Publication of IL148089A0 publication Critical patent/IL148089A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
IL14808900A 1999-08-17 2000-08-16 Baff receptor (bcma), an immunorgulatory agent IL148089A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14937899P 1999-08-17 1999-08-17
US18168400P 2000-02-11 2000-02-11
US18353600P 2000-02-18 2000-02-18
PCT/US2000/022507 WO2001012812A2 (en) 1999-08-17 2000-08-16 Baff receptor (bcma), an immunoregulatory agent

Publications (1)

Publication Number Publication Date
IL148089A0 true IL148089A0 (en) 2002-09-12

Family

ID=27386828

Family Applications (3)

Application Number Title Priority Date Filing Date
IL14808900A IL148089A0 (en) 1999-08-17 2000-08-16 Baff receptor (bcma), an immunorgulatory agent
IL148089A IL148089A (en) 1999-08-17 2002-02-10 Use of anti-bcma antibody to prepare a compound for the treatment of autoimmune disease, a disease associated with B cell proliferation and inflammation
IL230961A IL230961A (en) 1999-08-17 2014-02-13 Baff receptor that regulates the immune system

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL148089A IL148089A (en) 1999-08-17 2002-02-10 Use of anti-bcma antibody to prepare a compound for the treatment of autoimmune disease, a disease associated with B cell proliferation and inflammation
IL230961A IL230961A (en) 1999-08-17 2014-02-13 Baff receptor that regulates the immune system

Country Status (29)

Country Link
US (7) US7083785B2 (et)
EP (3) EP2314694A3 (et)
JP (4) JP4787439B2 (et)
KR (2) KR100897082B1 (et)
CN (1) CN100447244C (et)
AT (1) ATE360693T1 (et)
AU (1) AU780240B2 (et)
BG (1) BG106519A (et)
BR (2) BRPI0013391B8 (et)
CA (1) CA2383154C (et)
CZ (1) CZ300364B6 (et)
DE (1) DE60034579T3 (et)
DK (1) DK1210425T4 (et)
EA (1) EA004635B1 (et)
EE (1) EE05673B1 (et)
GE (1) GEP20053685B (et)
HK (1) HK1043608B (et)
HU (3) HU230583B1 (et)
IL (3) IL148089A0 (et)
IS (1) IS2955B (et)
MX (1) MXPA02001665A (et)
NO (2) NO331410B1 (et)
NZ (1) NZ517782A (et)
PL (2) PL207501B1 (et)
RS (1) RS51157B (et)
SK (2) SK288287B6 (et)
TR (1) TR200201063T2 (et)
UA (1) UA75049C2 (et)
WO (1) WO2001012812A2 (et)

Families Citing this family (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
GB9828628D0 (en) 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
US20050100548A1 (en) * 2001-07-24 2005-05-12 Biogen Idec Ma Inc. BAFF, inhibitors thereof and their use in the modulation of B-cell response
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
WO2000068378A1 (en) 1999-05-06 2000-11-16 National Jewish Medical And Research Center Tall-1 nucleic acid molecules, proteins, receptors and methods of use thereof
KR100897082B1 (ko) * 1999-08-17 2009-05-14 바이오겐 아이덱 엠에이 인코포레이티드 Ｂａｆｆ 수용체(ｂｃｍａ), 면역조절제
UA74798C2 (uk) * 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
PT1255558E (pt) * 2000-02-16 2006-11-30 Genentech Inc Anticorpos anti-april e células hibridoma
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US7371388B1 (en) * 2000-05-04 2008-05-13 Human Genome Sciences, Inc. Treatment of Sjogren's syndrome by administration of TR18 polypeptides
CA2408617A1 (en) * 2000-05-12 2001-11-22 Amgen Inc. Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
EP1294769B1 (en) * 2000-06-16 2011-01-05 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
AU2001288301A1 (en) 2000-08-18 2002-03-04 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
DE10049010A1 (de) * 2000-10-04 2002-04-18 Boehringer Ingelheim Int Transferrin-Polykation/DNS-Komplexe für die systemische Therapie von Tumorerkrankungen mit zytotoxischen Proteinen
ES2379977T3 (es) 2001-05-24 2012-05-07 Zymogenetics, Inc. Proteínas de fusión de taci-inmunoglobulina
WO2003014294A2 (en) * 2001-08-03 2003-02-20 Genentech, Inc. Tacis and br3 polypeptides and uses thereof
WO2003072713A2 (en) * 2002-02-21 2003-09-04 Biogen Idec Ma Inc. Use of bcma as an immunoregulatory agent
EP1551877A4 (en) * 2002-07-25 2006-01-18 Genentech Inc TACI ANTIBODIES AND THEIR USE
WO2004094620A2 (en) 2003-03-28 2004-11-04 Biogen Idec Ma Inc. Truncated baff receptors
WO2005000351A2 (en) * 2003-06-05 2005-01-06 Genentech, Inc. Combination therapy for b cell disorders
US20050163775A1 (en) * 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
EP1675609A1 (en) 2003-10-20 2006-07-05 Biogen Idec MA Inc. Therapeutic regimens for baff antagonists
EP1709072A1 (en) 2004-01-29 2006-10-11 Genentech, Inc. Variants of the extracellular domain of bcma and uses thereof
WO2006052493A1 (en) * 2004-11-04 2006-05-18 Genentech, Inc. Polypeptides that bind baff and/or april
CA2590461A1 (en) * 2004-12-23 2006-06-29 Laboratoires Serono S.A. Bcma polypeptides and uses thereof
NZ560285A (en) * 2005-01-28 2011-04-29 Biogen Idec Inc Use of baff to treat Th2-mediated conditions
AR059945A1 (es) 2005-08-09 2008-05-14 Zymogenetics Inc Metodos para tratar afecciones malignas de celulas b que utilizan una molecula de fusion taci-ig
AR059025A1 (es) 2005-08-09 2008-03-12 Zymogenetics Inc Metodos para el tratamiento y prevencion de proliferacion de celulas anormales utilizando moleculas de fusion taci
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
JP5905184B2 (ja) * 2005-10-13 2016-04-20 ヒューマン ジノーム サイエンシーズ， インコーポレイテッドＨｕｍａｎ Ｇｅｎｏｍｅ Ｓｃｉｅｎｃｅｓ， Ｉｎｃ． 自己抗体陽性疾患を有する患者の処置に使用するための方法および組成物
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
ES2618543T3 (es) 2005-11-23 2017-06-21 Genentech, Inc. Métodos y composiciones relacionados con ensayos de linfocitos B
US8211649B2 (en) 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
AR060935A1 (es) 2006-05-15 2008-07-23 Ares Trading Sa Metodos para tratar enfermedades autoinmunes utilizando una molecula de fusion taci- ig
MY158980A (en) 2008-07-17 2016-11-30 Novartis Ag Compositions and methods of use for therapeutic antibodies
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
EP2396035A4 (en) * 2009-02-12 2012-09-12 Human Genome Sciences Inc USE OF ANTAGONISTS OF PROTEIN STIMULATING LYMPHOCYTES B TO PROMOTE GRAFT TOLERANCE
US9034324B2 (en) 2009-03-10 2015-05-19 Biogen Idec Ma Inc. Anti-BCMA antibodies
WO2011028945A1 (en) 2009-09-03 2011-03-10 Genentech, Inc. Methods for treating, diagnosing, and monitoring rheumatoid arthritis
CN101781680B (zh) * 2009-10-19 2012-05-09 南通大学附属医院 测定对人baff-r基因启动子活性影响因素的方法
CN101781679B (zh) * 2009-10-19 2012-05-23 南通大学附属医院 人baff-r基因启动子活性的测定方法
WO2011108008A2 (en) * 2010-03-04 2011-09-09 Transgene Biotek Ltd. Antibody for targeted induction of apoptosis, cdc and adcc mediated killing of cancer cells, tbl-cln1
CN103502472B (zh) 2011-02-28 2017-06-06 弗·哈夫曼-拉罗切有限公司 生物标记物和用于预测对b‑细胞拮抗剂的响应的方法
UA112434C2 (uk) 2011-05-27 2016-09-12 Ґлаксо Ґруп Лімітед Антигензв'язувальний білок, який специфічно зв'язується з всма
BR112013028779B8 (pt) * 2011-05-27 2021-04-20 Glaxo Group Ltd proteína de ligação de antígeno ou imunoconjugado, imunoconjugado, composição farmacêutica, e, uso de uma composição
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
EP2809684A1 (en) 2012-01-31 2014-12-10 Genentech, Inc. Anti-ig-e m1' antibodies and methods using same
US10435474B2 (en) 2013-12-24 2019-10-08 Ossianix, Inc. Baff selective binding compounds and related methods
ES2959480T3 (es) 2014-02-07 2024-02-26 Univ Mcmaster Acoplador de células T - antígeno trifuncional y métodos y usos del mismo
CN106163547A (zh) 2014-03-15 2016-11-23 诺华股份有限公司 使用嵌合抗原受体治疗癌症
RU2751660C2 (ru) 2014-07-21 2021-07-15 Новартис Аг Лечение злокачественного новообразования с использованием гуманизированного химерного антигенного рецептора против всма
JP2017528433A (ja) 2014-07-21 2017-09-28 ノバルティス アーゲー 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
CN114621969A (zh) 2014-09-17 2022-06-14 诺华股份有限公司 用于过继免疫疗法的具有嵌合受体的靶向细胞毒性细胞
AU2015357526B2 (en) 2014-12-05 2022-03-17 Eureka Therapeutics, Inc. Chimeric antigen receptors targeting B-cell maturation antigen and uses thereof
CN113388036A (zh) 2014-12-05 2021-09-14 纪念斯隆-凯特琳癌症中心 靶向b-细胞成熟抗原的抗体及其用途
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
MY196625A (en) * 2015-04-13 2023-04-23 Pfizer Therapeutic Antibodies and Their Uses
PE20171653A1 (es) 2015-04-13 2017-11-13 Pfizer Receptores del antigeno quimerico dirigidos al antigeno de maduracion de celulas b
EP3286211A1 (en) 2015-04-23 2018-02-28 Novartis AG Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
WO2017027392A1 (en) 2015-08-07 2017-02-16 Novartis Ag Treatment of cancer using chimeric cd3 receptor proteins
WO2017091786A1 (en) 2015-11-23 2017-06-01 Novartis Ag Optimized lentiviral transfer vectors and uses thereof
CA3009709A1 (en) 2015-12-30 2017-07-06 Novartis Ag Immune effector cell therapies with enhanced efficacy
MX2018009700A (es) 2016-02-17 2019-01-24 Seattle Genetics Inc Anticuerpos contra bcma y su uso para tratar el cancer y los trastornos inmunitarios.
WO2017165683A1 (en) 2016-03-23 2017-09-28 Novartis Ag Cell secreted minibodies and uses thereof
US11136405B2 (en) * 2016-06-06 2021-10-05 Board Of Regents, The Unviersity Of Texas System BAFF-R antibodies and uses thereof
US11613572B2 (en) 2016-06-21 2023-03-28 Teneobio, Inc. CD3 binding antibodies
EP4050034B1 (en) 2016-09-14 2024-05-08 TeneoOne, Inc. Cd3 binding antibodies
WO2018111340A1 (en) 2016-12-16 2018-06-21 Novartis Ag Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
JP7254699B2 (ja) 2016-12-21 2023-04-10 テネオバイオ， インコーポレイテッド 抗ｂｃｍａ重鎖のみ抗体
EP3574005B1 (en) 2017-01-26 2021-12-15 Novartis AG Cd28 compositions and methods for chimeric antigen receptor therapy
EP3577134A1 (en) 2017-01-31 2019-12-11 Novartis AG Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
WO2018160731A1 (en) 2017-02-28 2018-09-07 Novartis Ag Shp inhibitor compositions and uses for chimeric antigen receptor therapy
WO2018201056A1 (en) 2017-04-28 2018-11-01 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
CA3062506A1 (en) 2017-05-12 2019-05-23 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
US11166985B2 (en) 2017-05-12 2021-11-09 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
EP3642237A2 (en) 2017-06-20 2020-04-29 Teneobio, Inc. Anti-bcma heavy chain-only antibodies
MA49565A (fr) 2017-07-11 2020-05-20 Compass Therapeutics Llc Anticorps agonistes qui lient cd137 humain et leurs utilisations
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
WO2019071358A1 (en) 2017-10-12 2019-04-18 Mcmaster University Y182T MUTATION T CELL ANTIGEN COUPLEUR AND METHODS AND USES THEREOF
JP2021501570A (ja) 2017-10-18 2021-01-21 ノバルティス アーゲー 選択的タンパク質分解のための組成物及び方法
US20210040205A1 (en) 2017-10-25 2021-02-11 Novartis Ag Antibodies targeting cd32b and methods of use thereof
US11718679B2 (en) 2017-10-31 2023-08-08 Compass Therapeutics Llc CD137 antibodies and PD-1 antagonists and uses thereof
US20210179709A1 (en) 2017-10-31 2021-06-17 Novartis Ag Anti-car compositions and methods
MA50860A (fr) 2017-11-01 2020-09-09 Juno Therapeutics Inc Récepterus chimériques d'antigène contre l'antigène de maturation des cellules b et polynucleotides codants
SG11202003501XA (en) 2017-11-01 2020-05-28 Juno Therapeutics Inc Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
CA3088095A1 (en) 2017-11-15 2019-05-23 Novartis Ag Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies
US11851497B2 (en) 2017-11-20 2023-12-26 Compass Therapeutics Llc CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
CN111727373A (zh) 2017-11-30 2020-09-29 诺华股份有限公司 靶向bcma的嵌合抗原受体及其用途
US20200368268A1 (en) 2018-01-08 2020-11-26 Novartis Ag Immune-enhancing rnas for combination with chimeric antigen receptor therapy
AU2019215031A1 (en) 2018-01-31 2020-08-20 Novartis Ag Combination therapy using a chimeric antigen receptor
EP3752203A1 (en) 2018-02-13 2020-12-23 Novartis AG Chimeric antigen receptor therapy in combination with il-15r and il15
EP3784351A1 (en) 2018-04-27 2021-03-03 Novartis AG Car t cell therapies with enhanced efficacy
WO2019213282A1 (en) 2018-05-01 2019-11-07 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
BR112020022879A2 (pt) 2018-05-11 2021-02-23 Crispr Therapeutics Ag métodos e composições para tratamento de câncer
WO2019227003A1 (en) 2018-05-25 2019-11-28 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
BR112020024351A2 (pt) 2018-06-01 2021-02-23 Novartis Ag moléculas de ligação contra bcma e usos das mesmas
US20210123075A1 (en) 2018-06-08 2021-04-29 Novartis Ag Compositions and methods for immunooncology
SG11202011830SA (en) 2018-06-13 2020-12-30 Novartis Ag Bcma chimeric antigen receptors and uses thereof
US11845797B2 (en) 2018-07-03 2023-12-19 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
US11110123B2 (en) 2018-07-17 2021-09-07 Triumvira Immunologics Usa, Inc. T cell-antigen coupler with various construct optimizations
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
EP3844265A2 (en) 2018-08-31 2021-07-07 Novartis AG Methods of making chimeric antigen receptor-expressing cells
AU2019331496A1 (en) 2018-08-31 2021-03-18 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
CA3123511A1 (en) 2018-12-20 2020-06-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
EA202192019A1 (ru) 2019-02-15 2021-11-02 Новартис Аг Производные 3-(1-оксо-5-(пиперидин-4-ил)изоиндолин-2-ил)пиперидин-2,6-диона и пути их применения
JP7488826B2 (ja) 2019-02-15 2024-05-22 ノバルティス アーゲー 置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
CN113412127A (zh) 2019-02-25 2021-09-17 诺华股份有限公司 用于病毒递送的介孔二氧化硅颗粒组合物
WO2020191316A1 (en) 2019-03-21 2020-09-24 Novartis Ag Car-t cell therapies with enhanced efficacy
US20220168389A1 (en) 2019-04-12 2022-06-02 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
US20220251152A1 (en) 2019-04-24 2022-08-11 Novartis Ag Compositions and methods for selective protein degradation
WO2020222176A1 (en) 2019-04-30 2020-11-05 Crispr Therapeutics Ag Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
CR20210622A (es) 2019-06-14 2022-06-27 Teneobio Inc Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
SG11202111943UA (en) 2019-07-02 2021-11-29 Hutchinson Fred Cancer Res Recombinant ad35 vectors and related gene therapy improvements
BR112022010206A2 (pt) 2019-11-26 2022-11-29 Novartis Ag Receptores de antígeno quiméricos e usos dos mesmos
WO2021123996A1 (en) 2019-12-20 2021-06-24 Novartis Ag Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
IL295878A (en) 2020-02-27 2022-10-01 Novartis Ag Methods for producing cells expressing a chimeric antigen receptor
JP2023516008A (ja) 2020-02-27 2023-04-17 ノバルティス アーゲー キメラ抗原受容体発現細胞を作製する方法
BR112022021690A2 (pt) 2020-04-29 2022-12-20 Teneobio Inc Anticorpos de cadeia pesada multispecíficos com regiões constantes de cadeia pesada modificadas
AU2021288224A1 (en) 2020-06-11 2023-01-05 Novartis Ag ZBTB32 inhibitors and uses thereof
JP2023531676A (ja) 2020-06-23 2023-07-25 ノバルティス アーゲー ３－（１－オキソイソインドリン－２－イル）ピぺリジン－２，６－ジオン誘導体を含む投与レジメン
JP2023536164A (ja) 2020-08-03 2023-08-23 ノバルティス アーゲー ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
KR20230058427A (ko) 2020-08-21 2023-05-03 노파르티스 아게 Car 발현 세포의 생체내 생성을 위한 조성물 및 방법
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
CN117597359A (zh) 2021-04-08 2024-02-23 马伦戈治疗公司 与tcr结合的多功能分子及其用途
AU2022267891A1 (en) 2021-04-27 2023-11-09 Novartis Ag Viral vector production system
KR20240037892A (ko) 2021-06-01 2024-03-22 트리움비라 이뮤놀로직스 유에스에이, 인크. 클라우딘 18.2 t 세포-항원 커플러 및 이의 용도
US11453723B1 (en) 2021-06-25 2022-09-27 Mcmaster University BCMA T cell-antigen couplers and uses thereof
EP4384201A2 (en) 2021-08-11 2024-06-19 Akso Biopharmaceutical, Inc. Methods of reducing production of iga, igm and/or igg using sbcma variants and fc fusion proteins thereof
AU2022330406A1 (en) 2021-08-20 2024-03-07 Novartis Ag Methods of making chimeric antigen receptor–expressing cells
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
WO2024089639A1 (en) 2022-10-26 2024-05-02 Novartis Ag Lentiviral formulations

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US6541224B2 (en) * 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
ES2210354T3 (es) 1996-03-14 2004-07-01 Human Genome Sciences, Inc. Factor de necrosis tumoral humano delta y epsilon.
EP2230307A1 (en) 1996-10-25 2010-09-22 Human Genome Sciences, Inc. Neutrokine alpha
AU5705898A (en) 1996-12-17 1998-07-15 Schering Corporation Mammalian cell surface antigens; related reagents
US5969102A (en) 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
CA2232743A1 (en) 1997-04-02 1998-10-02 Smithkline Beecham Corporation A tnf homologue, tl5
CA2285746C (en) 1997-04-16 2010-09-28 Amgen Inc. Osteoprotegerin binding proteins and receptors
JP2002504818A (ja) 1997-06-06 2002-02-12 リジェネロン ファーマシューティカルズ，インコーポレイテッド リガンドファミリーのｎｔｎ−２メンバー
CA2292835A1 (en) 1997-06-06 1998-12-10 Regeneron Pharmaceuticals, Inc. Ntn-2 member of tnf ligand family
AU9376498A (en) 1997-09-05 1999-03-22 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
CA2303615A1 (en) * 1997-09-12 1999-03-18 Jurg Tschopp April- a novel protein with growth effects
EP1012270A2 (en) * 1997-09-12 2000-06-28 Apotech R&D S.A. Kay - a novel immune system protein
WO1999013078A1 (en) 1997-09-12 1999-03-18 Biogen, Inc. Cysteine rich receptors-train
US6297367B1 (en) * 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
WO1999033980A2 (en) 1997-12-30 1999-07-08 Chiron Corporation Members of tnf and tnfr families
DE69921718T2 (de) * 1998-04-01 2005-12-22 Solvay Solexis, Inc., Wilmington Verträgliche Mischungen aus Polyvinylidenfluorid und aromatischem Polyimid
AU1467000A (en) 1998-11-04 2000-05-22 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The A novel tumor necrosis factor family member, drl, and related compositions and methods
GB9828628D0 (en) 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
US20060067933A1 (en) * 1999-01-07 2006-03-30 Gross Jane A Soluble receptor BR43x2 and methods of using
PT1141274E (pt) † 1999-01-07 2004-02-27 Zymogenetics Inc Receptor soluvel br43x2 e metodos para sua utilizacao
US7833529B1 (en) * 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
NZ513284A (en) * 1999-01-25 2003-10-31 Biogen Inc BAFF blocking agents and their use in the stimulation and inhibition of B-cells and immunoglobulins in immune responses
US6475986B1 (en) * 1999-02-02 2002-11-05 Research Development Foundation Uses of THANK, a TNF homologue that activates apoptosis
JP2002541779A (ja) 1999-02-24 2002-12-10 ザ ジュネラル ホスピタル コーポレーション シグナル伝達中間体のクローニング方法
AU3633000A (en) 1999-03-26 2000-10-16 Human Genome Sciences, Inc. Neutrokine-alpha binding proteins and methods based thereon
WO2000068378A1 (en) * 1999-05-06 2000-11-16 National Jewish Medical And Research Center Tall-1 nucleic acid molecules, proteins, receptors and methods of use thereof
KR100897082B1 (ko) 1999-08-17 2009-05-14 바이오겐 아이덱 엠에이 인코포레이티드 Ｂａｆｆ 수용체(ｂｃｍａ), 면역조절제
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
AU2001234953B2 (en) 2000-02-11 2006-03-16 Biogen Ma Inc. Heterologous polypeptide of the tnf family
PT1255558E (pt) † 2000-02-16 2006-11-30 Genentech Inc Anticorpos anti-april e células hibridoma
US20040013674A1 (en) 2001-04-27 2004-01-22 Christine Ambrose Taci as an anti-tumor agent
CA2408617A1 (en) 2000-05-12 2001-11-22 Amgen Inc. Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
EP1294769B1 (en) 2000-06-16 2011-01-05 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
CA2419661A1 (en) 2000-08-15 2002-03-07 Guo-Liang Yu Neutrokine-alpha and neutrokine-alpha splice variant
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
CA2467521A1 (en) 2001-11-16 2003-07-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
WO2003072713A2 (en) 2002-02-21 2003-09-04 Biogen Idec Ma Inc. Use of bcma as an immunoregulatory agent
US7083735B2 (en) 2003-09-03 2006-08-01 Laing David A High debris content strainer
BR112013028779B8 (pt) 2011-05-27 2021-04-20 Glaxo Group Ltd proteína de ligação de antígeno ou imunoconjugado, imunoconjugado, composição farmacêutica, e, uso de uma composição
FR3005792B1 (fr) 2013-05-16 2017-12-29 Parknplug Procede de gestion dynamique et previsionnel du rechargement electrique de batteries

Also Published As

Publication number Publication date
IL230961A0 (en) 2014-03-31
UA75049C2 (uk) 2006-03-15
EP2314694A2 (en) 2011-04-27
DK1210425T4 (en) 2015-08-10
JP2011063600A (ja) 2011-03-31
JP2014037434A (ja) 2014-02-27
JP2003507364A (ja) 2003-02-25
NZ517782A (en) 2004-01-30
US10494416B2 (en) 2019-12-03
EA200200261A1 (ru) 2002-08-29
BRPI0013391B1 (pt) 2018-09-11
US20180273605A1 (en) 2018-09-27
PL354661A1 (en) 2004-02-09
NO20020789L (no) 2002-04-08
DK1210425T3 (da) 2007-09-17
US20100040627A1 (en) 2010-02-18
MXPA02001665A (es) 2003-07-14
EP1210425B2 (en) 2015-06-17
EP1806143A2 (en) 2007-07-11
IL148089A (en) 2015-03-31
CZ2002579A3 (cs) 2002-05-15
EP1806143A3 (en) 2007-07-18
HK1043608B (zh) 2007-12-07
IS6273A (is) 2002-02-15
JP2011116790A (ja) 2011-06-16
EE200200071A (et) 2003-04-15
AU6911200A (en) 2001-03-13
US7691804B2 (en) 2010-04-06
HU1000128D0 (en) 2010-05-28
KR20020084842A (ko) 2002-11-11
HUP0203084A2 (en) 2002-12-28
DE60034579T2 (de) 2008-01-31
AU780240B2 (en) 2005-03-10
JP5379107B2 (ja) 2013-12-25
GEP20053685B (en) 2005-12-12
EP1806143B1 (en) 2016-06-15
JP5904985B2 (ja) 2016-04-20
EA004635B1 (ru) 2004-06-24
PL211786B1 (pl) 2012-06-29
DE60034579D1 (de) 2007-06-06
US20020165156A1 (en) 2002-11-07
PL207501B1 (pl) 2010-12-31
ATE360693T1 (de) 2007-05-15
US9650430B2 (en) 2017-05-16
YU10602A (sh) 2005-06-10
JP4787439B2 (ja) 2011-10-05
US20150139992A1 (en) 2015-05-21
CN1379815A (zh) 2002-11-13
EP2314694A3 (en) 2013-12-11
HU227008B1 (en) 2010-04-28
NO331410B1 (no) 2011-12-19
SK500172015A3 (et) 2002-07-02
KR100897082B1 (ko) 2009-05-14
CN100447244C (zh) 2008-12-31
US20200095305A1 (en) 2020-03-26
KR20090016772A (ko) 2009-02-17
CZ300364B6 (cs) 2009-04-29
IS2955B (is) 2016-12-15
HU227947B1 (en) 2012-06-28
RS51157B (sr) 2010-10-31
SK2292002A3 (en) 2002-07-02
HK1043608A1 (en) 2002-09-20
IL230961A (en) 2016-06-30
US7083785B2 (en) 2006-08-01
EP1210425A2 (en) 2002-06-05
BRPI0013391B8 (pt) 2021-05-25
CA2383154A1 (en) 2001-02-22
NO20020789D0 (no) 2002-02-18
NO20111232A1 (no) 2011-09-12
BG106519A (bg) 2003-04-30
DE60034579T3 (de) 2015-11-12
EP1210425B1 (en) 2007-04-25
TR200201063T2 (tr) 2002-10-21
NO344346B1 (no) 2019-11-11
BR0013391A (pt) 2002-07-09
SK288603B6 (sk) 2018-10-01
US20120214687A1 (en) 2012-08-23
EE05673B1 (et) 2013-08-15
WO2001012812A3 (en) 2001-09-07
CA2383154C (en) 2013-04-30
HU230583B1 (hu) 2017-02-28
US20020172674A1 (en) 2002-11-21
SK288287B6 (sk) 2015-07-01
US8828669B2 (en) 2014-09-09
WO2001012812A2 (en) 2001-02-22

Similar Documents

Publication Publication Date Title
IL148089A0 (en) Baff receptor (bcma), an immunorgulatory agent
HK1044710A1 (en) April receptor (bcma) and uses thereof
FR2796141B1 (fr) Dispositif d'initiation d'une composition energetique
FR2802455B1 (fr) Dispositif d'extracteur d'electrode
Wells The biological reductive dechlorination of chlorinated compounds in high rate anaerobic reactor.
Fardin The device of the double in Mikhail Bulgakov's short narratives
Dolgikh et al. Cherenkov radiation of channeled particles; Cherenkovskoe izluchenie kanalirovannykh chastits
光永貴之 Experimental analyses of the stability of biological communities

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed